ArticleLeukemia2016
Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia.
Open access · greenAbstract readLetter
In one paragraph
Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 59 citations in OpenAlex.
- Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.Journal of hematology & oncology · 2020Trial
- The Inv(16) Oncogene CBFB::MYH11 is Required for the Survival of Leukemia Cells in the Blood and Spleen, but not the Bone Marrow.Oncogene · 2026Article
- Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.Leukemia · 2026Article
- Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia.The Journal of molecular diagnostics : JMD · 2023Article
- Leukemic stem cells and therapy resistance in acute myeloid leukemia.Haematologica · 2023Review
- Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients withTurkish journal of haematology : official journal of Turkish Society of Haematology · 2022Review
- Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML.Leukemia · 2022Article
- Redundant mechanisms driven independently by RUNX1 and GATA2 for hematopoietic development.Blood advances · 2021Article
- Comprehensive analysis of mutations and clonal evolution patterns in a cohort of patients with cytogenetically normal acute myeloid leukemia.Molecular cytogenetics · 2021Article
- Review
- Dhx15 regulates zebrafish definitive hematopoiesis through the unfolded protein response pathway.Cancer science · 2021Article
- Core binding factor acute myelogenous leukemia-2021 treatment algorithm.Blood cancer journal · 2021Review
- Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers.Blood cancer discovery · 2021Article
- Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Characteristics of Cohesin Mutation in Acute Myeloid Leukemia and Its Clinical Significance.Frontiers in oncology · 2021Review
- CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia.The Journal of clinical investigation · 2020Article
- Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia.Anticancer research · 2020Article
- Clonal competition within complex evolutionary hierarchies shapes AML over time.Nature communications · 2020Article
- Splicing factor DHX15 affects tp53 and mdm2 expression via alternate splicing and promoter usage.Human molecular genetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
R SoodOncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
N F HansenComparative Genomics Analysis Unit, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
F X DonovanGenomics Core, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
B CarringtonZebrafish Core, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
D BucciComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
B MaskeriNIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
A YoungNIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
N S TrivediBioinformatics and Scientific Programming Core, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
J KohlschmidtComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
R M StoneMedical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard University, Boston, MA, USA.
M A CaligiuriComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
S C ChandrasekharappaGenomics Core, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
G MarcucciComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
J C MullikinComparative Genomics Analysis Unit, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
C D BloomfieldComprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
P LiuOncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
National Human Genome Research Institute · USNational Institutes of Health · USThe Ohio State University · USCity of Hope · USHarvard University · US
Funding
Inter- and Intra-Species Comparative SequencingZIBHG000196 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI THOMAS, JAMES · 2009 to 2025
$177.6MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MComparative Genomics Unit ResearchZIAHG200330 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI MULLIKIN, JAMES C · 2009 to 2022
$17.9MMOLECULAR PATHOGENESIS OF CHROMOSOME 16 INVERSION INHUMAN LEUKEMIAZIAHG000030 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI LIU, PAUL · 2009 to 2025
$15.8MNHGRI/DIR Genomics CoreZICHG200346 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI CHANDRASEKHARAPPA, SETTARA · 2010 to 2025
$14.5MPOSITIONAL CLONING OF THE MEN1 GENEZIAHG000029 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI CHANDRASEKHARAPPA, SETTARA · 2009 to 2025
$13.3MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MCancer and Leukemia Group B - Leukemia Correlative SciencesU10CA101140 · NCI · OHIO STATE UNIVERSITY · PI MARCUCCI, GUIDO · 2003 to 2013
$10.3MOSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8MITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4MMOLECULAR PATHOGENESIS OF CHROMOSOME 16 INVERSION INHUMAN LEUKEMIAZ01HG000030 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI LIU, PU PAUL · 1995 to 2008
$2.5MIntramural NIH HHS Z01 HG000030NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS U10 CA101140NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180861
Abstract
PubMed holds no abstract for this paper.
Indexed as
Chromosome InversionChromosomes, Human, Pair 16Chromosomes, Human, Pair 21Chromosomes, Human, Pair 8Clonal EvolutionMutationTranslocation, GeneticHumansLeukemia, Myeloid, AcuteRecurrence
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.